Waters (NYSE:WAT) Price Target Raised to $530.00

Waters (NYSE:WAT) had its price objective raised by TD Cowen from $515.00 to $530.00 in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the medical instruments supplier’s stock.

WAT has been the subject of a number of other reports. UBS Group raised Waters from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $375.00 to $490.00 in a research report on Wednesday, September 9th. Piper Sandler raised shares of Waters from a “neutral” rating to an “overweight” rating and upped their target price for the company from $400.00 to $480.00 in a research report on Thursday, August 27th. Weiss Ratings raised shares of Waters from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. JPMorgan Chase & Co. lifted their price target on shares of Waters from $400.00 to $435.00 in a research report on Wednesday, October 14th. Finally, Citigroup boosted their price target on shares of Waters from $425.00 to $470.00 and gave the company a “buy” rating in a research note on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $475.48.

Waters Price Performance

Shares of Waters stock traded up $4.84 during trading hours on Wednesday, reaching $457.92. 695,768 shares of the company’s stock were exchanged, compared to its average volume of 995,254. The business has a fifty day moving average of $434.72 and a two-hundred day moving average of $372.24. The company has a market capitalization of $44.99 billion, a P/E ratio of 196.53, a price-to-earnings-growth ratio of 2.62 and a beta of 1.16. The company has a quick ratio of 1.29, a current ratio of 1.86 and a debt-to-equity ratio of 0.32. Waters has a 1 year low of $282.77 and a 1 year high of $482.28.

Waters (NYSE:WAT) last posted its quarterly earnings results on Tuesday, November 3rd. The medical instruments supplier reported $4.10 EPS for the quarter, topping the consensus estimate of $4.00 by $0.10. The business had revenue of $1.77 billion for the quarter, compared to analyst estimates of $1.75 billion. Waters had a return on equity of 11.27% and a net margin of 3.58%. The company’s quarterly revenue was up 120.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.40 EPS. As a group, research analysts predict that Waters will post 14.65 earnings per share for the current fiscal year.

Institutional Trading of Waters

Several hedge funds have recently made changes to their positions in WAT. Pilgrim Global Advisors LLC purchased a new position in Waters in the 2nd quarter valued at approximately $466,131,171,000. BlackRock Inc. acquired a new position in Waters in the 2nd quarter valued at about $3,182,191,000. Aberdeen Group plc increased its position in Waters by 2,015.3% in the 3rd quarter. Aberdeen Group plc now owns 2,921,255 shares of the medical instruments supplier’s stock valued at $1,283,570,000 after acquiring an additional 2,783,151 shares during the period. Jupiter Topco LLC purchased a new stake in Waters during the 2nd quarter valued at approximately $623,921,000. Finally, Wellington Management Group LLP raised its stake in Waters by 69.2% during the 2nd quarter. Wellington Management Group LLP now owns 1,373,150 shares of the medical instruments supplier’s stock valued at $514,986,000 after acquiring an additional 561,824 shares during the last quarter. Institutional investors and hedge funds own 94.01% of the company’s stock.

Waters News Summary

Here are the key news stories impacting Waters this week:

• Positive Sentiment: Waters reported $1.77 billion in third-quarter 2026 revenue and raised its full-year guidance, signaling improved expectations for the business. Waters Corporation Reports $1.77 Billion in Third Quarter 2026 Revenue and Raises Full-Year Guidance
• Positive Sentiment: The company agreed to acquire MOBILion Systems, expanding its mass spectrometry and AI-powered proteomics capabilities. The strategic fit could broaden Waters’ technology offering, though the reported item does not quantify the deal’s financial impact. Waters Corporation Acquires MOBILion Systems
• Positive Sentiment: JPMorgan, Barclays, KeyCorp, TD Cowen, Citigroup, and RBC issued reports indicating higher price targets or strong potential appreciation, reinforcing a favorable analyst outlook. JPMorgan price target Barclays outlook KeyCorp outlook TD Cowen price target Citigroup price target RBC outlook

Waters Company Profile

Waters Corporation develops and supplies analytical instruments, software, and consumables used to identify, measure, and characterize chemical and biological materials. Its products include liquid chromatography and mass spectrometry systems, which help customers analyze complex samples.

The company serves pharmaceutical and biotechnology businesses, academic and government laboratories, and customers in fields such as food, environmental testing, and materials science. Waters operates internationally, with customers and operations across multiple regions.

Founded in 1958 by James L.